Clinical Trial

Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction

Study acronym: TRACE
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of a modified neoadjuvant immunotherapy plus chemotherapy (one cycle of Tislelizumab monotherapy followed by four cycles of Tislelizumab plus Docetaxel, Oxaliplatin and Capecitabine) in patients with locally advanced resectable adenocarcinoma of the esophagogastric junction (AEG).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-16.
Trial Details
NCT Number NCT06469060
Lead Sponsor Shanghai Chest Hospital
Conditions Esophageal Cancer
Enrollment 34 participants
Start Date 2024-06-19
Primary Completion 2025-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-01